RECRUITINGINTERVENTIONAL

Multiomic Diagnostics in Youth With Psychosis

Multiomic Diagnostics in Child and Adolescent Psychosis

About This Trial

Rady Children's Institute for Genomic Medicine seeks to understand the genomes and immune systems in 15 children and adolescents who are admitted to Rady Children's Hospital Child and Adolescent Psychiatry Service with psychotic symptoms or schizophrenia. Cutting-edge genome and protein sequencing technology will be used to better understand how immunological and genetic assessments may improve our ability to identify the cause of psychosis and impact care. The investigator also hopes to identify new genetic and/or autoimmune causes of psychosis that may inform new treatment for future patients.

Who May Be Eligible (Plain English)

Who May Qualify: Individual in whom one of the following criteria is met: 1. Child/adolescent admitted to the Rady Children's CAPS with symptoms of first break psychosis OR 2. Biological parents of child/adolescent enrolled in this study for the purposes of reflex testing. Family members are eligible for participation in this study if they are presumed genetically related to a patient participant. Who Should NOT Join This Trial: Child/Adolescent patients who do not meet any of the inclusion criteria, or those who: 1. Already received any prior whole genome sequencing or exome sequencing. 2. Unable to approach the family or patient for enrollment. 3. Unable to obtain willing to sign a consent form. 4. Family members are ineligible for participation in this study if: 1. They are known to not be genetically related to the child/adolescent patient participant 2. They are a member of a protected research population Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: Individual in whom one of the following criteria is met: 1. Child/adolescent admitted to the Rady Children's CAPS with symptoms of first break psychosis OR 2. Biological parents of child/adolescent enrolled in this study for the purposes of reflex testing. Family members are eligible for participation in this study if they are presumed genetically related to a patient participant. Exclusion Criteria: Child/Adolescent patients who do not meet any of the inclusion criteria, or those who: 1. Already received any prior whole genome sequencing or exome sequencing. 2. Unable to approach the family or patient for enrollment. 3. Unable to obtain informed consent. 4. Family members are ineligible for participation in this study if: 1. They are known to not be genetically related to the child/adolescent patient participant 2. They are a member of a protected research population

Treatments Being Tested

GENETIC

Genetic: Genomic sequencing and molecular diagnostic results, if any.

Genomic sequencing results may be used for diagnosis and treatment of participants.

DIAGNOSTIC_TEST

Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)

Whole Proteome programmable phage display immunoprecipitation sequencing will be used to diagnose known and novel autoantibodies.

Locations (1)

Rady Children's Hospital San Diego

San Diego, California, United States